DE60018833D1 - Verfahren zur Synthese von Nukleosidanaloga - Google Patents

Verfahren zur Synthese von Nukleosidanaloga

Info

Publication number
DE60018833D1
DE60018833D1 DE60018833T DE60018833T DE60018833D1 DE 60018833 D1 DE60018833 D1 DE 60018833D1 DE 60018833 T DE60018833 T DE 60018833T DE 60018833 T DE60018833 T DE 60018833T DE 60018833 D1 DE60018833 D1 DE 60018833D1
Authority
DE
Germany
Prior art keywords
synthesis
nucleoside analogues
nucleoside
analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60018833T
Other languages
German (de)
English (en)
Inventor
Robert William Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60018833D1 publication Critical patent/DE60018833D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE60018833T 1999-05-11 2000-05-09 Verfahren zur Synthese von Nukleosidanaloga Expired - Lifetime DE60018833D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13365199P 1999-05-11 1999-05-11

Publications (1)

Publication Number Publication Date
DE60018833D1 true DE60018833D1 (de) 2005-04-28

Family

ID=22459680

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60018833T Expired - Lifetime DE60018833D1 (de) 1999-05-11 2000-05-09 Verfahren zur Synthese von Nukleosidanaloga

Country Status (22)

Country Link
US (1) US6271370B1 (OSRAM)
EP (1) EP1052264B1 (OSRAM)
JP (1) JP2001011092A (OSRAM)
KR (1) KR100403900B1 (OSRAM)
CN (1) CN1275575A (OSRAM)
AR (1) AR028991A1 (OSRAM)
AT (1) ATE291582T1 (OSRAM)
AU (1) AU3401100A (OSRAM)
BR (1) BR0002089A (OSRAM)
CA (1) CA2307951A1 (OSRAM)
CZ (1) CZ20001710A3 (OSRAM)
DE (1) DE60018833D1 (OSRAM)
HU (1) HUP0001843A3 (OSRAM)
ID (1) ID25992A (OSRAM)
IL (1) IL136027A0 (OSRAM)
IN (1) IN186850B (OSRAM)
MX (1) MXPA00004532A (OSRAM)
PL (1) PL340109A1 (OSRAM)
RU (1) RU2200738C2 (OSRAM)
TR (1) TR200001340A2 (OSRAM)
YU (1) YU25500A (OSRAM)
ZA (1) ZA200002263B (OSRAM)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AU2005267051B2 (en) * 2004-07-21 2011-07-14 Gilead Sciences, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl pyrimidines and purines and their derivatives
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
CA2607021C (en) 2005-05-05 2013-10-29 Ardea Biosciences, Inc. Diaryl-purines, -azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
AU2006277769B2 (en) 2005-08-08 2011-06-02 Pulmagen Therapeutics (Synergy) Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
US8394836B2 (en) 2007-12-14 2013-03-12 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
ES2389752T3 (es) 2007-12-14 2012-10-31 Ardea Biosciences, Inc. Inhibidores de la transcriptasa inversa
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
CN102395586A (zh) 2009-02-17 2012-03-28 奇斯药制品公司 作为p38map激酶抑制剂的三唑并吡啶衍生物
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
US8927513B2 (en) * 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
EA201391230A1 (ru) 2011-02-25 2014-01-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов trk
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
EP2788345B1 (en) 2011-12-09 2020-06-10 Chiesi Farmaceutici S.p.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
EP2788348B1 (en) 2011-12-09 2016-10-19 Chiesi Farmaceutici S.p.A. Kinase inhibitors
DK2788349T3 (en) 2011-12-09 2017-01-30 Chiesi Farm Spa kinase inhibitors
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
CN105732639A (zh) 2012-06-29 2016-07-06 辉瑞大药厂 作为LRRK2抑制剂的4-(取代的氨基)-7H-吡咯并〔2,3-d〕嘧啶类
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
US9181242B2 (en) 2013-06-06 2015-11-10 Chiesi Farmaceutici S.P.A. Kinase inhibitors
PE20161323A1 (es) 2013-09-05 2016-11-25 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
JP2018507236A (ja) 2015-03-04 2018-03-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾロピリジン化合物及びその使用法
EP3350178B1 (en) 2015-09-14 2021-10-20 Pfizer Inc. Novel imidazo [4,5-c]quinoline and imidazo [4,5-c][1,5]naphthyridine derivatives as lrrk2 inhibitors
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
TW201730189A (zh) 2015-12-23 2017-09-01 吉斯藥品公司 激酶抑制劑
MA44131A (fr) 2015-12-23 2021-05-26 Chiesi Farm Spa Dérivés de 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urée et leur utlisation en tant qu'inhibiteurs de p38 mapk
AR107163A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
WO2017191098A1 (en) 2016-05-05 2017-11-09 F. Hoffmann-La Roche Ag Pyrazole derivatives, compositions and therapeutic use thereof
CR20190118A (es) 2016-09-06 2019-04-30 Hoffmann La Roche COMPUESTOS 8-(AZETIDIN-1-IL)-[1,2,4]TRIAZOLO[1,5-a]PIRIDINILO, COMPOSICIONES Y MÉTODOS DE UTILIZACIPON DE LOS MISMOS
EP3562809B1 (en) 2016-12-29 2021-06-09 F. Hoffmann-La Roche AG Pyrazolopyrimidine compounds and methods of use thereof
CN110494434B (zh) 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 吡唑并氯苯基化合物、其组合物及其使用方法
CR20190520A (es) 2017-05-22 2020-01-21 Hoffmann La Roche Composiciones y compuestos terapéuticos y métodos para utilizarlos
WO2018215390A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
CN111587250A (zh) 2018-01-15 2020-08-25 豪夫迈·罗氏有限公司 作为jak抑制剂的吡唑并嘧啶化合物
JP2021525802A (ja) 2018-06-01 2021-09-27 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ Ｐｉ３ｋに関連する疾患または障害に対する併用療法
CN114008051B (zh) 2019-06-18 2024-08-13 豪夫迈·罗氏有限公司 Jak激酶的吡唑并嘧啶砜抑制剂及其用途
JP7716993B2 (ja) 2019-06-18 2025-08-01 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｊａｋキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用
TW202115069A (zh) 2019-06-18 2021-04-16 瑞士商赫孚孟拉羅股份公司 Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207400A (ja) * 1985-03-11 1986-09-13 Nippon Zoki Pharmaceut Co Ltd ヌクレオシド化合物の製造方法
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4859677A (en) 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5246931A (en) 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5470857A (en) 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
AU3086495A (en) * 1994-08-02 1996-03-04 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5659023A (en) 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
BR9707185A (pt) 1996-01-23 1999-03-23 Glaxo Group Ltd Nucleosídeos de benzimidazol modificados como agentes antivirais

Also Published As

Publication number Publication date
HU0001843D0 (en) 2000-07-28
CN1275575A (zh) 2000-12-06
BR0002089A (pt) 2001-01-02
EP1052264A2 (en) 2000-11-15
ZA200002263B (en) 2001-12-24
AU3401100A (en) 2000-11-16
MXPA00004532A (es) 2002-03-08
HUP0001843A2 (hu) 2001-06-28
IL136027A0 (en) 2001-05-20
KR20010069193A (ko) 2001-07-23
ATE291582T1 (de) 2005-04-15
RU2200738C2 (ru) 2003-03-20
EP1052264A3 (en) 2001-06-13
CA2307951A1 (en) 2000-11-11
US6271370B1 (en) 2001-08-07
JP2001011092A (ja) 2001-01-16
YU25500A (sh) 2003-08-29
KR100403900B1 (ko) 2003-11-01
TR200001340A2 (tr) 2000-12-21
ID25992A (id) 2000-11-16
EP1052264B1 (en) 2005-03-23
AR028991A1 (es) 2003-06-04
HUP0001843A3 (en) 2001-09-28
PL340109A1 (en) 2000-11-20
CZ20001710A3 (cs) 2001-09-12
IN186850B (OSRAM) 2001-11-24

Similar Documents

Publication Publication Date Title
DE60018833D1 (de) Verfahren zur Synthese von Nukleosidanaloga
EP1066308A4 (en) IMPROVED METHODS OF SYNTHESIS OF OLIGONUCLEOTIDES
EP1427743A4 (en) SYNTHESIS OF PYRAZOLOPYRIMIDINES
DE50015014D1 (de) Verfahren zur Hydroformylierung von Olefinen
DE60114525D1 (de) Array-basierende Methoden zur Synthese von Nukleinsäuregemischen
DE50015005D1 (de) Verfahren zur katalytischen Durchführung von Hydroformylierungen
DE60221619D1 (de) Verfahren zur Reinigung von Synthesegas
ATE284759T1 (de) Verfahren zur befestigung von piezoelektrischen elementen
ATE258927T1 (de) Verbessertes verfahren zur herstellung von n- substituierte aminotetraline
DE60008315D1 (de) Verfahren zur Herstellung von Methylchlorid
DE59901861D1 (de) Verfahren zur katalytischen zersetzung von n 2?o
DE69819998D1 (de) Verfahren zur chemischen Synthese von Oligonukleotiden
EP0979233A4 (en) Method for solution phase synthesis of oligonucleotides
DE50014421D1 (de) Verfahren zur Hydrierung von Aceton
DE60201384D1 (de) Verfahren zur Synthese von Harnstoff
DE60108668D1 (de) Verfahren zur herstellung von phenethylamin-derivaten
DE60028076D1 (de) Verfahren zur stereoselektiven synthese zyklischer aminosäuren
DE60129907D1 (de) Verfahren zur Reinigung von Isophthalonitril
DE69824366D1 (de) Verfahren zur Synthese von Alkylpolyglucosiden
DE60111808D1 (de) Verfahren zur Entfernung von Katalysatorresten
DE60112515D1 (de) Verfahren zur Disproportionierung von Isopentan
DE60019606D1 (de) Verfahren zur herstellung von substituierten pyrimidinen
DE59900737D1 (de) Verfahren zur Synthese von Feststoffen
DE69709303D1 (de) Verfahren zur Synthese von Diamant
DE69817550D1 (de) Verfahren zur sprachsynthese

Legal Events

Date Code Title Description
8332 No legal effect for de